Companion Diagnostics – A Strategic Review from an IP Perspective (TechVision)
29-Sep-2016
Global
Technology Research
D6BB-01-00-00-00
HC02675-GL-TR_18877
This study highlights opportunities and risks in diagnostics/companion diagnostics sector from patenting perspective. It provides an overview of key intellectual property (IP) issues, recent cases for diagnostics and gene patenting in the United States and their business impact. It also provides an overview of the patenting activity in the area of companion diagnostics and strategic recommendations for formulating an appropriate IP strategy.
1.0 Executive Summary
2.1 Research Objectives
2.2 What Is Companion Diagnostics?
2.3 Why Is Companion Diagnostics so Important?
2.4 Expansive R&D Makes IP Protection a Key Issue in Diagnostics/Pharmaceutical Sector
3.1 Key IP Issues Relevant to CDx
3.2 TRIPS Agreement Provides Member States Flexibility to Notify Various Categories That Are Excluded from Patenting
3.3 Patentability Criteria for Diagnostics in Major Markets
3.4 Patenting Opportunities for Diagnostics
3.5 Recent Cases Involving Diagnostics/Gene Patenting
4.1 Myriad Genetics – Company and Product Overview
4.2 AMP vs. Myriad Case – Facts of the Case and Timeline
4.3 AMP vs. Myriad Case – Key Issues and Arguments of Litigants
4.4 AMP vs. Myriad Case – Decision of the District Court
4.5 Decision of the Court of Appeals for the Federal Circuit
4.6 First appeal to the US Supreme Court
4.7 AMP vs. Myriad Case – Decision of the US Supreme Court
4.8 Business Impact of AMP vs. Myriad Case in Diagnostics Sector
4.9 Business Impact of AMP vs. Myriad Case in Therapeutics Sector
5.1 History of Genes and Gene Patenting
5.1 History of Genes and Gene Patenting (continued)
5.1 History of Genes and Gene Patenting (continued)
6.1 Standards of Gene Patentability
6.2 Standards of Gene Patentability: Schematic of Guidelines
6.3 Standards of Gene Patentability: Schematics Explained
6.4 Factors for “significantly different”: Weighing towards Patent Eligibility
6.5 Factors for “significantly different”: Weighing against Patent Eligibility
7.1 Patent Research Scope and Concepts
7.2 Top 20 Patent Holders in the Area of Companion Diagnostics
7.3 Patent Office-wise Distribution of Companion Diagnostics Patent Portfolios, 1996–2016
7.4 Publication Year-wise Distribution of Companion Diagnostics Patent Portfolio, 2008–2016
8.1 Abbott – CDx Patents
8.1 Abbott – CDx Patents (continued)
8.2 Denovo Biomarkers Inc.
8.3 Expression Pathology Inc.
8.3 Expression Pathology Inc. (continued)
8.4 Immune Therapy Holdings AB
8.4 Immune Therapy Holdings AB (continued)
8.5 The University of California
8.6 Sanofi
8.7 Roche (Genentech)
8.8 Boston University
8.9 Genomic Vision
8.10 Zensun Shanghai Science & Technology Ltd.
9.1 Key Findings
9.2 Strategic Recommendations
Legal Disclaimer
10.1 The Frost & Sullivan Story
10.2 Value Proposition: Future of Your Company & Career
10.3 Global Perspective
10.4 Industry Convergence
10.5 360º Research Perspective
10.6 Implementation Excellence
10.7 Our Blue Ocean Strategy
Speak directly with our analytics experts for tailored recommendations.
Recent related Healthcare research
17 Nov 2026 | Global | Frost Radar
Frost Radar™: Quantum-Grade Sensor Technology Ecosystem for Healthcare Applications, 2026
Quantum-grade sensors are advancing healthcare by leveraging quantum phenomena to enable highly sensitive, precise, and non-invasive measurements of biological signals and physiological parameters. These innovations enhance diagnostic accuracy, disease monitoring, brain activity measurement, and ear...
16 Nov 2026 | North America | Frost Radar
Frost Radar™: Healthcare Data Interoperability Platforms and Integration Engines in North America, 2026
This Frost Radar™ analyzes the healthcare data platform and integration engine vendors that enable healthcare organization to improve the exchange, utilization, contextualization, and management of clinical, operational, financial, and administrative data. Data issues, AI adoption, and solution gove...
03 Nov 2026 | North America | Market Research
Enterprise Imaging Market, United States, 2025–2030
Enterprise imaging is no longer a technology upgrade. It is becoming the operating model for imaging across the provider organization, and the next investment cycle will decide which vendors lead it. This study gives vendors, ecosystem partners, and provider leaders a 360-degree view of that shift, ...
02 Nov 2026 | Global | Market Research
Continuous Glucose Monitoring Market, Global, 2026
The global continuous glucose monitoring (CGM) market is undergoing a fundamental transformation as the technology evolves from a prescription-led glucose monitoring device into an AI-connected metabolic intelligence ecosystem. Market expansion is increasingly driven by the emergence of over-the-cou...
28 Oct 2026 | Global | Frost Radar
Frost Radar™: Health Monitoring Wearable Solutions, 2026
The health monitoring wearables industry is undergoing a profound transformation as competitive advantage shifts from device hardware to integrated digital health ecosystems. Market leaders are differentiating through clinically validated health insights, longitudinal data platforms, AI-enabled anal...
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.